JP2007516278A5 - - Google Patents

Download PDF

Info

Publication number
JP2007516278A5
JP2007516278A5 JP2006546881A JP2006546881A JP2007516278A5 JP 2007516278 A5 JP2007516278 A5 JP 2007516278A5 JP 2006546881 A JP2006546881 A JP 2006546881A JP 2006546881 A JP2006546881 A JP 2006546881A JP 2007516278 A5 JP2007516278 A5 JP 2007516278A5
Authority
JP
Japan
Prior art keywords
cisapride
pat
cns
moiety
unrestricted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006546881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007516278A (ja
JP4740152B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NO2004/000399 external-priority patent/WO2005061483A2/en
Publication of JP2007516278A publication Critical patent/JP2007516278A/ja
Publication of JP2007516278A5 publication Critical patent/JP2007516278A5/ja
Application granted granted Critical
Publication of JP4740152B2 publication Critical patent/JP4740152B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006546881A 2003-12-23 2004-12-23 末梢性５−ｈｔ受容体の修飾因子 Expired - Fee Related JP4740152B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301924 2003-12-23
DKPA200301924 2003-12-23
PCT/NO2004/000399 WO2005061483A2 (en) 2003-12-23 2004-12-23 Modulators of peripheral 5-ht receptors

Publications (3)

Publication Number Publication Date
JP2007516278A JP2007516278A (ja) 2007-06-21
JP2007516278A5 true JP2007516278A5 (enExample) 2008-08-14
JP4740152B2 JP4740152B2 (ja) 2011-08-03

Family

ID=34707211

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006546881A Expired - Fee Related JP4740152B2 (ja) 2003-12-23 2004-12-23 末梢性５−ｈｔ受容体の修飾因子

Country Status (10)

Country Link
US (1) US7834010B2 (enExample)
EP (1) EP1701951B1 (enExample)
JP (1) JP4740152B2 (enExample)
AT (1) ATE457309T1 (enExample)
AU (1) AU2004303722B2 (enExample)
CA (1) CA2551171C (enExample)
DE (1) DE602004025508D1 (enExample)
DK (1) DK1701951T3 (enExample)
ES (1) ES2340855T3 (enExample)
WO (1) WO2005061483A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
WO2007007072A1 (en) * 2005-07-07 2007-01-18 Bio-Medisinsk Innovasjon As 5-htx modulators
JP5075818B2 (ja) * 2005-07-22 2012-11-21 ファイザー株式会社 ５ｈｔ４受容体アゴニストとしてのインダゾールカルボキサミド誘導体
ITMI20062230A1 (it) * 2006-11-22 2008-05-23 Acraf Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
WO2009050248A1 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Substituierte piperidino-dihydrothienopyrimidine
UA99927C2 (uk) * 2007-11-12 2012-10-25 Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. Медикамент, який є активним при невропатичному болі
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
EP2400962B1 (de) 2009-02-27 2017-11-08 Boehringer Ingelheim International GmbH Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
GB0905641D0 (en) 2009-04-01 2009-05-13 Serodus As Compounds
EP2512243B1 (en) 2009-12-17 2016-04-06 Merck Sharp & Dohme Corp. Quinoline amide m1 receptor positive allosteric modulators
WO2011124525A1 (de) 2010-04-08 2011-10-13 Boehringer Ingelheim International Gmbh Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
MX364929B (es) * 2013-03-20 2019-05-14 Suven Life Sciences Ltd Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4.
NZ720879A (en) 2013-12-16 2017-05-26 Suven Life Sciences Ltd Indazole compounds as 5-ht4 receptor agonists
EP3183232B1 (en) * 2014-08-22 2023-05-03 The Arizona Board of Regents on behalf of The University of Arizona Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation
CN111606837A (zh) * 2020-06-15 2020-09-01 千辉药业（安徽）有限责任公司 一种维格列汀的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4494547A (en) 1981-03-30 1985-01-22 North Carolina Central University 2H-isoindolediones, their synthesis and use as radiosensitizers
ATE180785T1 (de) 1992-03-12 1999-06-15 Smithkline Beecham Plc Kondensierte indol-derivate als 5-ht4-rezeptor- antagonisten
CZ289031B6 (cs) * 1994-09-27 2001-10-17 Janssen Pharmaceutica N. V. Deriváty N-substituovaných piperidinylových bicyklických benzoátů
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US20010031751A1 (en) * 1997-12-05 2001-10-18 Smithkline Beecham P.L.C. Pharmaceuticals
JPH11292846A (ja) * 1998-02-10 1999-10-26 Hokuriku Seiyaku Co Ltd ベンズアミド誘導体及びそれを含有する医薬
AR022338A1 (es) 1999-02-04 2002-09-04 Hokuriku Pharmaceutical Un compuesto de benzamida, medicamento que lo contiene, y uso para la manufactura de un medicamento para el tratamiento o prevencion de una enfermedad digestiva o para mejorar la movilidad del tracto gastrointestinal.
JP3398111B2 (ja) * 1999-02-04 2003-04-21 北陸製薬株式会社 ベンズアミド誘導体及びそれを含有する医薬
AU2001275326C1 (en) * 2000-06-07 2006-09-21 Aryx Therapeutics Treatment of gastroesophageal reflux disease using piperidine derivatives
US6552004B1 (en) * 2000-10-30 2003-04-22 Universite De Montreal Delivery system for entrapping charged macromolecules and a method for preparing same
US6598534B2 (en) * 2001-06-04 2003-07-29 Raytheon Company Warhead with aligned projectiles
US6624163B2 (en) * 2001-11-29 2003-09-23 Hoffman-La Roche Inc. Benzothiazole derivatives

Similar Documents

Publication Publication Date Title
JP2007516278A5 (enExample)
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
BG66102B1 (bg) Карбаматни производни на арилалкиламини
WO2007063385A3 (en) Spirocyclic amine histamine-3 receptor antagonists
ATE488496T1 (de) Histamin-3-rezeptorantagonisten
WO2005075436A3 (en) Novel inhibitors of glutaminyl cyclase
EP2096919A4 (en) SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] CHINAZOLINE DERIVATIVES SUITABLE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDER AND ANGIOGENIC RELATED DISEASES
WO2008050341A3 (en) Novel psychotropic agents having glutamate nmda activity
WO2007138431A3 (en) Azabicyclic ether histamine-3 antagonists
UA88719C2 (ru) Антагонисты рецепторов гистамина-3
AR066641A1 (es) Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas
TNSN08205A1 (en) Use of a cb1 antagonist for treating negative symptoms of schizophrenia
NO20071326L (no) Kondenserte trisykliske derivater for behandling av psykotiske forstyrrelser
WO2006121560A3 (en) Methods and compositions for treatment of cns disorders
AU2002258808A1 (en) Humanized antibodies
IL194947A0 (en) Aryl-4-ethynyl-isoxazole derivatives
IL190867A0 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
JP2007516193A5 (enExample)
WO2005084655A8 (en) 1-aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer’s disease
ATE457309T1 (de) Modulatoren von peripheren 5-ht-rezeptoren
JP2005527477A5 (enExample)
EP1799258A4 (en) PROCESS FOR TREATING ANGIOGENESIS
EP1814537A4 (en) MACROCYCLIC TERTIARY AMIN BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
JP2008526706A5 (enExample)
MX2007003587A (es) Antagonistas de los receptores de histamina-3.